Neviran (Nevirapine)

Nevirapine, the active ingredient in Neviran, is a non-nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of HIV-1 infection in adults, adolescents and children as part of combination antiretroviral therapy. GNH USA supplies Neviran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Neviran is manufactured under EU Good Manufacturing Practice and is available for bulk and packaged supply.

Neviran (nevirapine) is used in antiretroviral regimens targeting the HIV-1 replication pathway.

- HIV-1 infection (treatment-naïve adults): achieves viral load reduction and CD4 count improvement when combined with other antiretrovirals. - HIV-1 infection (treatment-experienced adults): provides an alternative NNRTI option to overcome resistance in combination therapy. - HIV-1 infection (pediatric patients ≥2 years): contributes to viral suppression as part of age-appropriate combination regimens.

Neviran may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: general tiredness. - Headache: transient cranial pain. - Abdominal pain: mild stomach discomfort. - Dizziness: occasional light-headedness.

Serious or Rare Side Effects: - Stevens-Johnson syndrome: severe skin detachment requiring immediate discontinuation. - Hepatic failure: signs of liver injury such as jaundice or elevated enzymes. - Severe hypersensitivity: fever, eosinophilia, and systemic reactions. - Liver toxicity: hepatitis or fulminant liver damage. - Severe neutropenia: markedly reduced white blood cell count. - Life-threatening skin reactions: toxic epidermal necrolysis.

Before initiating Neviran, clinicians should consider several safety precautions to minimize risk.

- Monitor liver function: obtain baseline transaminases and repeat periodically during therapy. - Assess for rash: discontinue immediately if severe cutaneous reactions develop. - Avoid in known hypersensitivity: do not prescribe to patients with prior nevirapine allergy. - Use cautiously in hepatitis B or C co-infection: increased risk of hepatic adverse events. - Pregnancy considerations: evaluate risk-benefit ratio and follow local guidelines for antiretroviral use in pregnancy. - Store at room temperature: keep in original container, protect from moisture and heat.

Neviran can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Ritonavir: markedly increases nevirapine plasma concentrations, raising toxicity risk. - Efavirenz: may reduce nevirapine efficacy when co-administered. - St. John's wort: induces metabolism leading to decreased nevirapine levels. - Protease inhibitors (except ritonavir): can increase nevirapine-related adverse effects. - Carbamazepine and other enzyme inducers: lower nevirapine exposure, compromising antiviral activity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: nevirapine may reduce hormonal efficacy; consider alternative contraception. - Warfarin: monitor INR more frequently as nevirapine can affect anticoagulant control.